Metabolomic Profile of Arthrospira platensis from a Bulgarian Bioreactor-A Potential Opportunity for Inclusion in Dietary Supplements.

The present study aims to elucidate the metabolomic profile of Arthrospira platensis grown in a bioreactor in Bulgaria. The results show that Arthrospira platensis has a high content of mannose, 137.02 mg g-1, and vitamin A (retinol)-10.3 µg/100 g. High concentrations of calcium, sulfur, and zinc distinguish its elemental composition. The freeze-dried powder contained 15.81 ± 0.45% dietary fiber, 50.16 ± 0.25% total protein content, and 1.22 ± 0.11% total fat content. Among the unsaturated fatty acids with the highest content is α-linolenic acid (25.28%), while among the saturated fatty acids, palmitic acid prevails (22.55%). Of the sterols in the sample, ß-sitosterol predominated. There is no presence of microcystins LR, RR, YR, and nodularin. Therefore, Arthrospira platensis grown in a Bulgarian bioreactor is safe for use in the pharmaceutical and food industries. Many of the organic compounds found have applications in medicine and pharmacology and play an important role in biochemical processes in the body. Therefore, Arthrospira platensis grown in Bulgaria has a high potential for use as an independent food supplement or in combination with other natural products.

Chemical Compositions, Pharmacological Properties and Medicinal Effects of Genus Passiflora L.: A Review.

Practically all aboveground plants parts of Passiflora vines can be included in the compositions of dietary supplements, medicines, and cosmetics. It has a diverse chemical composition and a wide range of biologically active components that determine its diverse pharmacological properties. Studies related to the chemical composition of the plant are summarized here, and attention has been paid to various medical applications-(1) anti-inflammatory, nephroprotective; (2) anti-depressant; (3) antidiabetic; (4) hepatoprotective; (5) antibacterial and antifungal; and (6) antipyretic and other. This review includes studies on the safety, synergistic effects, and toxicity that may occur with the use of various dietary supplements based on it. Attention has been drawn to its application in cosmetics and to patented products containing passionflower.

Subchronic effects of ligands of cannabinoid receptors on learning and memory processes of olfactory bulbectomized rats.

The brain endocannabinoid system has been shown to play a role in many physiological processes, including mood, learning and memory. It is also involved in the pathogenesis of anxiety, depression, mood disorders, as well as neurodegenerative disorders, although the exact mechanisms by which cannabinoid receptors interfere in these disorders are not well established. The aim of the present study was to evaluate the effects of cannabinoid ligands HU­210 (CB1 receptor agonist) and SR 141716A (CB1 receptor antagonist) on learning and memory processes of rats with depressive - like state, induced by bilateral olfactory bulbectomy. The bilateral olfactory bulbectomy (OBX) is a validated model of depression, which can be used also as an animal model of Alzheimer's disease. We found that the subchronic treatment of OBX rats with HU 210 and SR 141716A exerted modulatory effect on rat's performance in both active avoidance (shuttle box) and passive avoidance (step through) tests. HU 210 ameliorated the memory deficits of OBX rats; however, the scores of the sham­operated controls had not been reached. SR 141716A modified the avoidance performance in OBX rats and showed a memory enhancing effect in the sham­operated rats. Our findings suggest that CB1 receptors might be involved in avoidance learning and memory acquisition in OBX rats.

Subchronic Central Administration of Cannabinoid Ligands Modulates Nociception in Bulbectomized Rats.

INTRODUCTION: Endocannabinoid system is involved in neuropsychiatric disorders such as major depression. The bilaterally olfactory bulbectomized rat is widely used as an animal model of depression. The removal of the olfactory bulbs produces behavioural, physiological, and neurochemical alterations resembling clinical depression. There is increasing evidence that highlights the important role of cannabinoid signalling in depression and nociception. AIM: To investigate the effect of CB1 receptor agonist HU 210 and CB1 receptor antagonist SR 141716A administered icv subchronically (for 7 days) on nociception of rats with model of depression - bilateral olfactory bulbectomy (OBX). MATERIAL AND METHODS: Experimental model of depression - bilateral olfactory bulbectomy (OBX). Bilaterally olfactory bulbectomized rats were used as an experimental model of depression. HU 210 (5 µg) or SR 141716A (3 µg) were infused icv for 7 consecutive days, starting 15 days after the olfactory bulbectomy. Nociception was examined by applying paw pressure test (analgesy-meter) evaluating the rat pain threshold. On day 7, five minutes after the last microinjection, the rats were tested in an analgesy-meter and their mechanically evoked pain responses were measured in arbitrary units (AU). RESULTS: Microinjections of HU 210 (5 µg) significantly decreased the pain threshold in olfactory bulbectomized rats, while SR 141716A (3 µg) exerted antinociceptive effect by increasing the pain threshold. CONCLUSIONS: Data point to an involvement of CB1 receptors in depression-like behaviour and nociception in olfactory bulbectomized rats and support the data for the association between depressive disorder and pain pathways.